Patent SG-11201901667T-A (SG)
Title: Combination therapy with liposomal antisense oligonucleotides
Inventor: ASHIZAWA ANA TARI
IPC: A61P35/02
Filed: 2017-09-15
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111H111011111111111111110111110100111111111111111101110111011111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/053232 Al 22 March 2018 (22.03.2018) WIP0 I PCT (51) International Patent Classification: A61K 31/7088 (2006.01) A61P 35/02 (2006.01) Published: A61K 31/711 (2006.01) — with international search report (Art 21(3)) — before the expiration of the time limit for amending the (21) International Application Number: claims and to be republished in the event of receipt of PCT/US2017/051723 amendments (Rule 48.2(h)) (22) International Filing Date: — with sequence listing part of description (Rule 5.2(a)) 15 September 2017 (15.09.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/395,680 16 September 2016 (16.09.2016) US 62/487,277 19 April 2017 (19.04.2017) US (71) Applicant: BIO-PATH HOLDINGS, INC. [US/US]; 4710 Bellaire Blvd., Suite 210, Bellaire, TX 77401 (US). (72) Inventor: ASHIZAWA, Ana Tani; c/o Bio-Path Holdings, INC., 4710 Bellaire Blvd., Suite 210, Bellaire, TX 77401 _ (US). Agent: SCHNEPP, Amanda S.J.; Parker Highlander (74) = PLLC, 1120 S. Capital of Texas Highway, Bldg. One, Suite 200, Austin, TX 78746 (US). = Designated States (unless otherwise indicated, for every (81) = kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = = = = = = = = _ Designated States (unless otherwise indicated, for every — (84) _ _ kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). = = = = — = 1-1 ei M ei en in (54) Title: COMBINATION THERAPY WITH LIPOSOMAL ANTISENSE OLIGONUCLEOTIDES ---- (57) : Provided herein are methods of treating a cancer in a patient comprising administration of an effective amount of a GC nuclease-resistant polynucleotide that hybridizes to the translation initiation site of a Grb2 nucleic acid in the patient and either a Bcr- © Abl tyrosine kinase inhibitor (e.g., dasatinib) or a cytidine analogue (e.g., decitabine or cytarabine). The cancer may be Ph+ and/or Bcr- el Abl positive chronic myelogenous leukemia or acute myeloid leukemia or myelodysplastic syndrome. C